Millennium Management’s ImmunityBio IBRX Stock Holding History

Millennium Management’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-100,000	Closed	-$537K	–	6178
2024 Q1	$537K	Buy	+100,000	New	+$453K	﹤0.01%	4763
2021 Q2	–	Sell	-100,000	Closed	-$2.37M	–	6752
2021 Q1	$2.37M	Buy	+100,000	New	+$2.59M	﹤0.01%	3371
2016 Q2	–	Sell	-50,000	Closed	-$411K	–	3342
2016 Q1	$411K	Hold	50,000	–	–	﹤0.01%	2618
2015 Q4	$867K	Buy	+50,000	New	+$742K	﹤0.01%	2371

Other funds holding IBRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Millennium Management's IBRX Position: Q2 2026 in Review

Millennium Management increased its ImmunityBio (IBRX) stake by 293% in Q2 2026, buying an estimated $31.5M and bringing the position to 5,579,793 shares worth $48.9M. The position accounts for 0.02% of the portfolio, ranked #905.

Millennium Management first reported a position in IBRX in Q1 2016 and has held it in 37 quarters since. 405 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

Millennium Management held 5,579,793 shares of ImmunityBio worth $48.9M as of Q2 2026.
Millennium Management bought 4,159,549 ImmunityBio shares in Q2 2026, an estimated $31.5M.
ImmunityBio made up 0.02% of Millennium Management's portfolio in Q2 2026, its #905 holding.
Millennium Management first reported a position in ImmunityBio in Q1 2016 and has held it in 37 quarters since.
405 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.